New pill targets MYC cancers in early trial
NCT ID NCT05546268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participants will take the drug daily in 28-day cycles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Centre
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics (START) Mountain Region
West Valley City, Utah, 84119, United States
-
University of California San Diego
San Diego, California, 92037, United States
-
University of Kansas Cancer Center
Lawrence, Kansas, 66044, United States
-
Virginia Cancer Specialists Research Institute
Fairfax, Virginia, 22031, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can a pill keep lung cancer from returning after surgery?
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks